Han, E., Lee, Y., Lee, B., Kang, E. S., & Cha, B. (2020). Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial. J Clin Med.
Citación estilo ChicagoHan, Eugene, Yong-ho Lee, Byung-Wan Lee, Eun Seok Kang, and Bong-Soo Cha. "Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Controlled With Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial." J Clin Med 2020.
Cita MLAHan, Eugene, et al. "Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Controlled With Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial." J Clin Med 2020.